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Aim: The EPICHRONIC (EPIdemiology of CHRONIC diseases) project investigated the pos-
sibility of developing common procedures for French and Spanish electronic health care data-
bases to enable large-scale pharmacoepidemiological studies on chronic diseases. A feasibility 
study assessed the prevalence of type 2 diabetes mellitus (T2DM) in Navarre and the Basque 
Country (Spain) and the Midi-Pyrénées region (France).
Patients and methods: We described and compared database structures and the availability 
of hospital, outpatient, and drug-dispensing data from 5.9 million inhabitants. Due to differ-
ences in database structures and recorded data, we could not develop a common procedure to 
estimate T2DM prevalence, but identified an algorithm specific to each database. Patients were 
identified using primary care diagnosis codes previously validated in Spanish databases and a 
combination of primary care diagnosis codes, hospital diagnosis codes, and data on exposure 
to oral antidiabetic drugs from the French database.
Results: Spanish and French databases (the latter termed Système National d’Information Inter-
Régimes de l’Assurance Maladie [SNIIRAM]) included demographic, primary care diagnoses, 
hospital diagnoses, and outpatient drug-dispensing data. Diagnoses were encoded using the Inter-
national Classification of Primary Care (version 2) and the International Classification of Diseases, 
version 9 and version 10 (ICD-9 and ICD-10) in the Spanish databases, whereas the SNIIRAM 
contained ICD-10 codes. All data were anonymized before transferring to researchers. T2DM 
prevalence in the population over 20 years was estimated to be 6.6–7.0% in the Spanish regions 
and 6.3% in the Midi-Pyrénées region with ~2% higher estimates for males in the three regions.
Conclusion: Tailored procedures can be designed to estimate the prevalence of T2DM in 
population-based studies from Spanish and French electronic health care records.
Keywords: epidemiology, pharmacoepidemiology, electronic health care database, cross-
national study, population-based study, type 2 diabetes mellitus
Introduction
Cross-national studies that use health care databases can be useful to compare the 
epidemiology of diseases and drug exposures between countries. Recently, some 
projects have compared national databases to identify possible common extraction 
models. These projects included North European databases1 and European prescrip-
tion databases (Pharmacoepidemiological Research on Outcomes and Therapeutics 
by a European Consortium [PROTECT] project).2–4 This latter project demonstrated 
the feasibility of assessing drug exposure and pharmacovigilance signals in various 
national databases. Another example is the European Collaboration for Healthcare 
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Optimization (ECHO) project,5 a European Health Services 
Research Program that analyzed unwarranted variations in 
medical practice and health care outcomes, and was based on 
hospital databases from several European countries.
Nevertheless, health care systems and databases are often 
diverse and fragmented.6 Hence, cross-national research 
initiatives are still scarce and often include only some of the 
available health information. Initiatives that build infrastruc-
ture for the efficient reuse of health care data for epidemio-
logical research have been launched in recent years, such 
as the European Medical Information Framework (EMIF) 
project. This project currently collects information on around 
52 million European citizens from diverse data sources from 
regions within six European countries (including hospital 
data from the Barcelona region, but no French data).7
The use of health administrative data within each Euro-
pean country has a longer history than cross-national data 
and has become common practice in public health research 
in both Spain and France. In Spain, one of the most widely 
used databases is the Minimum Basic Data Set (MBDS) 
with information on all hospital discharges in the National 
Health System.8 Other important resources used in epide-
miological studies in Spain are the Primary Care Electronic 
Medical Record System,9 the Database for Pharmacoepide-
miologic Research in Primary Care (Base de Datos para la 
Investigación Farmacoepidemiológica en Atención Primaria; 
BIFAP) database for pharmacovigilance studies,10 the mor-
tality register,11 and the population directory database.12 
In France, most epidemiology or pharmacoepidemiology 
studies are conducted within the National Inter-Scheme 
Health Insurance database (Système National d’Information 
Inter-Régimes de l’Assurance Maladie;  SNIIRAM), which 
links outpatient, hospital, and civil status data for the entire 
French population (67 million inhabitants).13,14 The structure 
of the SNIIRAM and its data are described in the follow-
ing sections. The general beneficiary sample (Echantillon 
Généraliste des Bénéficiaires; EGB) is a 1/97 sample from 
the SNIIRAM (~600,000 individuals) and is mostly used to 
assess frequent conditions.13,14
The EPICHRONIC (EPIdemiology of CHRONIC dis-
eases) study was part of the REFBIO project, a trans-Pyre-
nean cooperation network for biomedical research created to 
promote competitive health research.15 The aim of the EPI-
CHRONIC study was to assess the possibility of developing 
common procedures in French and Spanish electronic health 
care databases and to carry out large-scale epidemiologic 
studies on chronic diseases. The specific objectives were to 
compare the data available in these databases and to conduct 
a feasibility study to assess the prevalence of type 2 diabetes 
mellitus in the early 2010s within the databases from three 
regions located on both sides of the Pyrenees.
Patients and methods
Design and setting
This population-based cross-sectional study was conducted 
in the Midi-Pyrénées region (southern France, 3 million 
inhabitants) and two autonomous communities located in 
northern Spain: the Basque Country (2.2 million inhabitants) 
and Navarre (0.7 million inhabitants).
For the French part of the study, we used the SNIIRAM 
database restricted to Midi-Pyrénées inhabitants. In France, 
the national insurance system covers all citizens. Hospital-
izations are reimbursed at about 80% of their costs, whereas 
outpatient costs, including drugs, vary between 15% and 70% 
of the total. The remaining are supported by mutual funds. 
However, there is a list of long-term diseases (LTDs) that 
allow full reimbursement of costs related to these conditions, 
and low-income patients benefit from full insurance cover 
without an advance payment.16
The Regional Health Systems of the Basque Country 
and Navarre are part of the Spanish National Health System 
(SNHS), which is a quasi-federal decentralized system where 
the regional governments of the 17 autonomous communi-
ties have full responsibility for policy making, planning, and 
financing at a regional level. In turn, each region is organized 
into basic health zones, the locus for primary care provision. 
Navarre consists of 57 basic health zones and the Basque 
Country consists of 139, each of which has a team of general 
practitioners, nurses, pediatricians, and other health care 
workers. The health care coverage provided by the SNHS 
is practically universal and is financed by general taxes 
and health services such as hospitalization, and diagnostic 
procedures are free of charge for all citizens. A fraction of 
medication costs are paid by patients within a cost-sharing 
scheme that is based on their employment and income status, 
established in Spain since July 2012.17 In the Spanish regions, 
all patients with type 2 diabetes mellitus are managed by pri-
mary care teams, and their data are recorded in the Primary 
Care Electronic Medical Record System, named Atenea in 
Navarre and Osabide-AP in the Basque Country.
Database comparison
We described and compared Spanish and French databases 
from different perspectives. First, we described and compared 
the database structures of all hospital, outpatient, and drug-
dispensing data. Second, we described and compared the 
legislative regulation regarding access and linkage of these 
databases. Results of this comparative study were used to 
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define the method used to identify type 2 diabetes mellitus 
in these databases.
Assessment of the prevalence of type 2 
diabetes mellitus
Due to differences between databases, we could not develop 
a common identification process but constructed specific 
algorithms for each database to identify cases of type 2 
diabetes mellitus.
Patients were considered to have type 2 diabetes mellitus 
in Navarre if, at the time of data extraction on May 15, 2014, 
the T90 code of the International Classification of Primary 
Care, version 2 (ICPC-2) was stated in the Atenea records. 
In the Basque Country, patients were considered to have this 
disease if, at the time of data extraction on February 12, 2015 
(Osabide-AP), they had a diagnosis with a code beginning 
with 250 from the International Classification of Diseases, 
version 9, clinical modification (ICD-9CM) in Osabide-AP, 
after excluding patients with any code relating to type 1 
diabetes mellitus (250.01; 250.03; 250.11; 250.13; 250.21; 
250.23; 250.31; 250.33; 250.41; 250.43; 250.51; 250.53; 
250.61; 250.63; 250.71; 250.73; 250.81; 250.83; 250.91; 
250.93). A recent study on type 2 diabetes mellitus ICPC-2 
codes in Navarre showed a sensitivity of 98%, a specificity 
of 99%, and a positive predictive value of 92%.18
In France, the 2011–2013 SNIIRAM data restricted to the 
Midi-Pyrénées region were used to estimate the prevalence 
of type 2 diabetes mellitus in 2012. In the SNIIRAM, there 
was no specific data relating to primary care diagnoses. Only 
the LTD diagnoses on full expenditure reimbursement are 
reported by the general practitioners and secondarily encoded 
by the health insurance physicians using the ICD-10.13,19 
Type 2 diabetes mellitus is one of these conditions (ICD-
10 E11 code). However, LTDs are often under-recorded in 
practice.13,14 Because all patients with type 2 diabetes mellitus 
cannot be identified using the corresponding LTD, we com-
bined three sources to identify these patients in the French 
Midi-Pyrénées region in 2012: the LTD ICD-10 code for type 
2 diabetes mellitus, the hospital ICD-10 codes (as primary, 
related, or associated diagnosis), and the chronic exposure 
to oral antidiabetic drugs (OADs), defined by at least three 
OADs dispensed (corresponding to 3 months of treatment) 
during a 6-month period. Moreover, to rule out the differential 
diagnoses of type 2 diabetes mellitus, we excluded patients 
with an LTD or hospital diagnosis code for another disease 
that led to hyperglycemia as well as patients with chronic 
exposure to systemic glucocorticoids or antiprotease drugs 
during the year previous to the first identification of type 2 
diabetes mellitus in 2012. The full algorithm is indicated in 
the “Supplementary material” section.
Age-specific prevalences were estimated according to sex 
and region; the crude and age–sex-adjusted overall preva-
lences with 95% CI were estimated for each region using 
the European Standard Population 2013.
Ethical considerations
This study, which was observational in design and retrospec-
tive in nature, used data that were irreversibly anonymized 
prior to transfer to the research team. The study was con-
ducted according to the amended Declaration of Helsinki, 
the International Guidelines for Ethical Review of Epide-
miological Studies, and the Spanish and French laws on data 
protection and patients’ rights. The protocol for the Spanish 
part of the study was approved by the Ethics Committee of 
Navarre (Project 67/2013, session on October 30, 2013). The 
protocol for the French part of the study was approved by 
a convention with the Midi-Pyrénées Regional Directory of 
Health Insurance in October 2014.
Results
Comparisons between databases
In France, outpatient data, hospital data, and health status 
are linkable for all beneficiaries (virtually the whole French 
population, 67 million inhabitants) because of individual 
irreversible anonymous numbering. These data are kept in a 
huge digital warehouse, the SNIIRAM.13,14 The SNIIRAM’s 
simplified architecture is shown in Figure 1. The Inter-
Scheme Consumption Data (Données de Consommation 
Inter-Régimes; DCIR) set includes administrative data and all 
outpatient reimbursed health expenditures. The Program for 
the Medicalization of Information Systems (Programme de 
Médicalisation des Systèmes d’Information; PMSI) includes 
data on inpatient care in public and private hospitals.13,14 Infor-
mation regarding health status is held in a separate registry 
by the National Institute of Statistics and Economic Studies 
(INSEE). Until now, only the date of death has been linked to 
the SNIIRAM, but the causes of death should become available 
soon. No detailed individual socioeconomic data are available 
in France except that on universal coverage for low-income 
patients.13,14,20 The main variables useful for epidemiological 
and pharmacoepidemiological studies are described in Table 1.
Data for Spanish databases are generally gathered at 
regional level; unlike the French data, they are not routinely 
combined into a unique national database. They have the 
same architecture in the Navarre and Basque Country and 
correspond to similar datasets as those used in the French 
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SNIIRAM (Figure 2). One of the most exhaustive databases 
is the Primary Care Electronic Medical Record System, 
which contains outpatient data and includes demographic 
information (date of birth, sex, basic health zone the patient 
belongs to), visits to primary care services (data and type), 
health problems, lifestyle, detailed clinical data, laboratory 
results, and drug prescription data. It has some variations in 
structure and the coding system depending on the autono-
mous community and period. The ICD-9-CM, ICD-10CM 
version adapted to Spanish health system, and ICPC-2 are 
all used.
For this study, the ICPC-2 was used in Navarre and the 
ICD-9-MC was used in the Basque Country. The validity 
of the information contained in these data sets has recently 
begun to be assessed. Results suggest that they are valid to 
assess the prevalence of cardiovascular risk factors, such 
as type 2 diabetes mellitus,18,21 although more studies are 
required to assess validity to conduct other types of pop-
ulation-based surveillance studies. Another database with 
outpatient information is the outpatient drug-dispensing 
database, with information on drugs dispensed at retail 
pharmacies. The electronic prescription system was intro-
duced to primary care in the Basque Country and Navarre 
in 2012 and 2014, respectively. More recently (2016–2017), 
prescriptions for specialized care have been included from 
both regions. Since the introduction of this new system, data 
from prescriptions and drug-dispensing have been gathered 
into a unique database for Navarre. For the Basque  Country, 
this can be extracted through the Osakidetza  Business 
Intelligence system, the business intelligence system that 
extracts information from the different administrative health 
care databases in the region. Regarding hospital data, they 
are recorded in the MBDS, which provides clinical and 
sociodemographic information on all hospital discharges 
in the National Health System, including diagnoses and 
procedures, coded according to the International Classifica-
tion of Diseases (ICD-10-ES from January 2016). It is less 
detailed than the French PMSI (Table 1). Several studies on 
the validity of MBDS conducted more than 1 decade ago 
have identified important reliability problems,22 although 
more recent study suggests that data quality has improved.23 
However, there is a need for more studies on the validity of 
specific MBDS codes.24 In addition, there are two other data 
sets that can be internally linked with the aforementioned 
data sets at an individual level: the mortality registry, with 
information on date and cause of death (since 2016, coded 
using ICD-10-ES), and the population register, which collects 
individual demographic and socioeconomic data.
Ethical approval is required in both countries to access 
these data sets for research purposes. In France, all requests 
for SNIIRAM extractions are sent to the Health Data Institute 
(Institut National des Données de Santé; INDS). Two autho-
rizations are mandatory from the National Data Protection 
Commission (Commission Nationale de l’Informatique et des 
Libertés; CNIL) regarding data protection and from an inde-
pendent methodological committee (Comité d’Expertise pour 
Figure 1 Simplified architecture of the SNIIRAM.
Abbreviations: DCIR, Données de Consommation Inter-Régimes (Inter-Scheme Consumption Data); HAD, Hospitalisation à Domicile (home hospitalization); MCO, 
Médecine, Chirurgie, Obstétrique (medicine, surgery, obstetrics); PMSI, Programme de Médicalisation des Systèmes d’Information (Program for the Medicalization of 
Information Systems); PSY, psychiatry; SNIIRAM, Système National d’Information Inter-Régime de l’Assurance Maladie (National Health Insurance Information System); SSR, 
Services de Suite et de Réadaptation (after care and rehabilitation).
PMSI datamart
SNIIRAM
Medical data
Costly long-term diseases
Occupational accidents
Occupational diseases
Sick leave
Demographic data
Age, sex, place of
residency, insurance
scheme, benefit from the
universal health coverage
PMSI MCO, PSY, SSR, HAD
Entry and release dates
Principal, related and associated diagnoses
Procedures
Costly drugs
Special unit; intensive care, palliative care, etc
National Institute of
Statistics and
Economic Studies
(INSEE)
Date of death
Out-of-hospital reimbursements
Date, who prescribes and who dispenses the care
For drugs: name, form, quantity dispensed
DCIR datamart
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Table 1 Main variables contained in French and Spanish health care databases
Variables Spain France
Demographics
Date of registration of the patient in the 
information system
Yes No
Date of diabetic onset Yes (date of registration of the first diabetic 
episode: not necessarily means date of 
diabetic onset) 
Necessitates algorithms to identify the first diagnosis 
code or the first antidiabetic drug dispensing
Sex Yes Yes
Birth date Yes (year) Yes (year)
Birth place Not always No
Working status Active/retired Active/retired
Pharmaceutical copayment category (proxy 
of socioeconomic class)
Yes Beneficiary of the Couverture Médicale Universelle 
Complémentaire status for low-income patients; 
socioeconomic deprivation index available by 
geographical area
Living area Basic health zone (5000–20,000 inhabitants) Ilots Regroupés pour l’Information Statistique (IRIS): 
areas of 2000 inhabitants for main cities; municipalities’ 
boundaries in the case of <2000 habitants
Education level Compulsory, high school, university; not 
available in Basque Country
No
Nationality Yes (probably biased) No
Occupation No Some insurance schemes correspond to specific 
occupations
Date of death Yes Yes
Cause of death Yes (in the mortality register, ICD-10-ES) No (being implemented)
Out-of-hospital examination, procedures, and health care
Code of the examination/care Yes (ICPC-2 classification and PGD in 
Navarre, and ICD-9 in Basque Country)
Yes, using a specific national classification
Date of care Yes Yes 
Physician who has prescribed Yes Yes
Health care provider Yes Yes
Results Yes No
Primary care data
Long-term disabling disease Yes (ICPC-2 classification, PGD, and ICD-9 
in Basque Country)
Yes (ICD-10)
Diagnosis for each visit Yes No
Date of visit Yes Yes
Physician Yes (anonymous identifier) Yes (identifier and specialty)
Clinical data (blood pressure, weight, height) Yes No
Lifestyle data (smoking, alcohol consumption, 
physical activity)
Yes No
Out-of-hospital drug dispensing*
Code of the drugs Yes, using ATC codes, except for many but 
not all over-the-counter drugs
Yes, using Club Inter Pharmaceutique (CIP) codes. 
Over-the-counter drugs are not recorded
Date of dispensing Yes Yes 
Number of units dispensed Yes Yes 
Physician who has prescribed Yes Yes 
Pharmacist provider Yes Yes 
Prescription data Yes No
Hospital data
Dates of entry and of release Yes Yes
Diagnosis Yes (ICD-9-MC at the moment of data 
extraction and ICD-10-ES from January 2016)
One main diagnosis ±1 related diagnosis and 
unlimited associated diagnoses (ICD-10)
Specific departments (intensive care unit, 
palliative care, etc)
Yes Yes
Procedures Yes, date, and codes Yes, date, and codes
Exposure to expensive drugs No Yes, date, and code of the drug
Exposure to non-expensive drugs No No
Note: *In Navarre, from 2014 onward, there was a unique database for drug dispensing, which included prescriptions.
Abbreviations: ATC, anatomical, therapeutic, chemical classification; ICD, International Classification of Diseases; ICPC-2, International Classification of Primary Care, 
version 2; PGD, patient general data.
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les Recherches, les Etudes et les Evaluations dans le domaine 
de la Santé; CEREES) according to a new law published in 
2016.25 In Spain, procedures are defined at a regional level 
and, in all cases, the project must be approved by an ethics 
committee and by the Health Department of the Government 
of each region. In Navarre and the Basque Country, the Health 
Department nominates an internal coordinator for the project, 
who supervises the data extraction procedures and guarantees 
fulfillment of the law on personal data protection. Mandatory 
conditions are that the files are anonymized and that the data 
exportation process follows both the Spanish Constitutional 
Act 15/1999 of 13 December on personal data protection26 
and the law 41/2002 of 14 November, which concerns clinical 
information issues.27
Prevalence of type 2 diabetes mellitus
Out of the population over 20 years of age at data extraction, 
the number of patients who had type 2 diabetes mellitus 
in Navarre and Basque Country was 32,638 and 132,455, 
respectively, leading to a crude prevalence of 6.62% (95% 
CI: 6.55–6.89) in Navarre and 7.01% (95% CI: 6.98–7.05) in 
the Basque Country (Table 2). In the Midi-Pyrénées region, a 
total of 141,669 patients were identified with type 2  diabetes 
mellitus. Of these, 21.9% were identified using only the 
outpatient drug data, 11.0% using only the LTD codes, 6.2% 
using only the in-hospital diagnosis codes, and the remaining 
60.9% using at least two of these three sources (Figure 3). 
This led to a crude prevalence of 6.26% (95% CI: 6.23–6.29).
Age–sex-adjusted prevalences were 6.19 (95% CI: 6.16–
6.22) for the French region, 6.84 (95% CI: 6.76–6.91) for 
Navarre, and 6.97 (95% CI: 6.93–7.01) for the Basque Coun-
try. There were statistically significant differences between 
the regions, especially between the French region and the 
Basque Country (0.8% lower). The prevalence was signifi-
cantly higher among males in the three regions (Table 2), 
and geographical differences were greater for males than 
females, with data 1.1% lower in the Midi-Pyrénées region 
than the Basque Country for males, and 0.4% for females.
Results relative to the age–sex prevalences for type 2 dia-
betes mellitus are given in Table 3. They increased with age 
and were higher in males in most age groups for all regions, 
with some exceptions in populations aged <35 years, where it 
was higher in females, especially in the French region. There 
were no relevant differences in the age-specific prevalence 
across regions, apart from the lower estimates observed 
in France compared to Spain for patients aged >65 years, 
especially in women, and the slightly higher prevalence in 
France for women aged <60 years.
Discussion
This study shows that base-specific procedures that share 
common grounds, but account for the particularities of each 
database, need to be developed to conduct cross-national 
epidemiological studies using French and Spanish electronic 
health care databases. The database-specific algorithms 
developed in this study to identify type 2 diabetes mellitus 
provided prevalence estimates between 6% and 7% in all 
three regions. They were 2% higher in males than females 
in all three regions and up to 20% higher in people aged 
>75 years, especially males.
This study demonstrates the feasibility of such approaches, 
provided that in-depth comparative analysis of database 
structures and contents in relation to the pathology under 
consideration is carried out beforehand. Indeed, using the 
Figure 2 Simplified architecture of Spanish databases.
Abbreviations: MBDS, Minimum Basic Data Set; PCIS, primary care information system.
MBDS database
Out-of-hospital drug
prescriptions
Prescribed drugs
PCIS database
Out-of-hospital drug dispensing
dispensed drugs
Demographic data
Age, sex, place of
residency, vital status
Hospital stays
Dates, main and secondary diagnoses,
procedures, destination at discharge
Being implemented: clinical constants and
laboratory test results
Mortality registry
Date of death
Cause of death
Population registry
Birth place, occupation,
educational level
Medical data
Diagnoses
Clinical constants
Cardiovascular risk
factors
Physical activity
Education (diet, etc)
Laboratory results
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same algorithm in different databases has been suggested to 
cause a major risk of error.28 Similarly, the EMIF project7 has 
shown that different strategies need to be adopted to identify 
a particular condition (such as type 2 diabetes mellitus) when 
handling distinct sources of health data that have heteroge-
neous characteristics.
The procedure designed to identify patients with type 2 
diabetes mellitus in the Spanish regions was based on the 
specific codes for this disease in the Primary Care Electronic 
Medical System. This procedure is similar to that developed 
by Roberto et al7 for databases from a primary care setting 
and is similar to that used by Vinagre et al29 in the Primary 
Care Electronic Medical System of Catalonia. The codes 
used in our study to identify type 2 diabetes mellitus have 
been validated in the Navarre database,18 and also in other 
regions, such as Madrid.30 In the Basque Country, the quality 
of the codification of diagnoses in the electronic health care 
Table 2 Prevalence of type 2 diabetes mellitus in Navarre, Basque Country, and Midi-Pyrénées expressed as percentages with 95% CIs
Basque Country (n=1,888,830) Navarre (n=493,443) Midi-Pyrénées (n=2,260,948)
Crude prevalence
Females 6.14 (6.09, 6.19) 5.60 (5.51, 5.98) 5.51 (5.47, 5.55)
Males 7.94 (7.88, 7.99) 7.48 (7.38, 7.86) 7.08 (7.03, 7.13)
Total 7.01 (6.98, 7.05) 6.62 (6.55, 6.89) 6.26 (6.23, 6.29)
Age-adjusted prevalence by sex
Females 5.51 (5.46,5.55) 5.34 (5.25,5.43) 5.07 (5.03, 5.11)
Males 8.43 (8.37, 8.49) 8.33 (8.21, 8.45) 7.32 (7.26, 7.37)
Age–sex-adjusted prevalence 6.97 (6.93, 7.01) 6.84 (6.76, 6.91) 6.19 (6.16, 6.22)
Figure 3 Combination of three sources to identify 141,669 prevalent French patients with type 2 diabetes mellitus.
Note: Numbers indicate the numbers and percentages of patients with type 2 diabetes mellitus identified using each source alone and combinations of sources.
Abbreviations: LTD, long-term disease; PMSI, Programme de Médicalisation des Systèmes d’Information (Program for the Medicalization of Information Systems); OADs, 
oral antidiabetic drugs.
6, 737
8,831
Total: 141,669
PMSI
total=47,739
OADs
total=110,561
LTD
total=90,872
31,061
47,329
15,540
10,905
21,266
Table 3 Prevalence of type 2 diabetes mellitus according to age 
and sex expressed as percentages
Age  
group  
(years)
Basque Country Navarre Midi-Pyrénées
Males Females Males Females Males Females
20–24 0.11 0.11 0.08 0.10 0.07 0.16
25–29 0.18 0.17 0.12 0.17 0.16 0.38
30–34 0.31 0.28 0.34 0.29 0.39 0.51
35–39 0.66 0.44 0.66 0.43 0.77 0.78
40–44 1.34 0.75 1.54 0.93 1.44 1.18
45–49 2.89 1.39 3.06 1.58 2.92 2.04
50–54 5.64 2.64 5.88 2.67 5.40 3.63
55–59 9.68 4.91 9.92 4.75 9.06 5.76
60–64 14.77 7.67 14.42 7.01 13.39 8.22
65–69 19.57 11.66 17.94 10.53 16.73 10.97
70–74 22.78 15.64 23.47 15.20 18.92 13.06
75–79 24.55 18.56 22.41 17.64 20.40 14.41
80–84 24.66 20.54 25.38 19.64 19.63 14.77
85–89 23.16 20.42 22.29 20.80 17.02 12.98
≥90 16.43 15.89 19.14 18.80 14.65 11.33
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records for primary care is also high.31 Nevertheless, studies 
on the quality and exhaustiveness of this type of data source 
in Spain are still needed.
In the French region, the procedure used to identify 
these patients was based on information from the SNIIRAM 
database, which is now frequently used for epidemiological 
purposes at a national level.13,19 The information available in 
the SNIIRAM is based on an irreversibly anonymous identi-
fier, which makes validation studies difficult.13,19 To reinforce 
the identification of patients with diabetes mellitus, we used 
a combination of variables, which is a common process for 
studies in the SNIIRAM.13,19 The results were highly consis-
tent with the Spanish results.
The prevalences estimated in this study are in line with 
those provided in the seventh edition of the IDF diabetes 
atlas,32 which showed an estimated prevalence for the 
2015 adult Spanish population aged 20–79 years of 10.4 
( age-adjusted on 2001 World Health Organization global 
structure of population: 7.7) and 7.4 (age-adjusted: 5.3) for 
the French population. Navarra and the Basque Country have 
among the lowest diabetes prevalences in Spain, a finding that 
could be related to the lower prevalence of obesity compared 
to other Spanish regions.33 The higher prevalence in Spanish 
regions compared to France is similar to those reported in 
the literature.32
Our results showed a similar effect for age and sex in 
the three regions, with a gradual increment in prevalence, 
particularly in those aged 55–75 years, and a constantly 
higher prevalence in males than females of about 2–3 points. 
This is similar to previous studies that have demonstrated an 
increased prevalence of type 2 diabetes mellitus with increas-
ing age, particularly in males.34–38 The higher prevalence 
in young women in France could be because, although the 
corresponding LTD and hospital codes related to gestational 
diabetes were removed, some of these patients may have 
been captured.
The main strengths of this study are that it was based 
on recent health data from >5.9 million people from three 
regions of Spain and France and that it provides an exhaus-
tive exploration of common and different fields from the 
main electronic health care databases used in research in 
both countries.
One of the main limitations of assessing type 2 diabetes 
mellitus was that it was based on registered data, so that 
patients who had the disease but had not been diagnosed 
were not included. A national population-based survey study 
conducted in Spain estimated an overall global incidence of 
diabetes of 13.8%, of which about 6.0% of the population 
had unknown diabetes.33 Another study, conducted in the 
Basque Country,39 showed an overall prevalence of 10.6%; 
of this proportion, 4.3% were not aware they had diabetes. 
As pointed out earlier, a second limitation is that the iden-
tification of patients with type 2 diabetes mellitus was not 
validated in all the sources used in this study. However, our 
results are consistent with the published literature, which 
is reassuring considering the risk of misdiagnosis. Of note, 
the procedure used in Spain allowed the identification of 
patients with type 2 diabetes mellitus treated by diet only 
(not receiving any antidiabetic medication) whereas, in 
France, those treated by diet only but without a specific LTD 
or hospital code could not be captured. However, 22.0% of 
the identified patients in the French database had no data 
on OAD prescriptions (Figure 3), whereas a French study 
estimated that, in 2010, 11% of patients were treated by diet 
only and 12% by insulin only.40 Consequently, we may have 
captured most patients treated by diet only in France, despite 
no visit data from general practitioners. A third limitation is 
that there was 2 years difference between the Spanish and 
French data extraction due to accessibility issues. However, 
there is no reason to expect large differences in prevalences 
within this 2-year period.
Conclusion
These results provide more evidence on the recently stated 
need to develop a common public health research infra-
structure at a European level to facilitate the reuse of health 
administrative databases for research purposes.41 The poten-
tial of health administrative data to advance developments 
in public health is being widely recognized, but important 
study is needed to overcome major obstacles regarding 
accessibility, legal issues, record linkage, integration, and 
data validation. Our study shows the possibility and benefits 
of reusing these data transnationally for research purposes 
to better understand the epidemiology of type 2 diabetes 
mellitus. We were able to achieve comparable estimates of 
prevalences “between” the Navarre, the Basque Country, 
and the Midi-Pyrénées regions, but with a slight gradient 
from less to more prevalence in the Midi-Pyrénées and the 
Basque Country. This could be the first step toward more 
combined studies across regions and countries that are based 
on monitoring patients with type 2 diabetes mellitus using 
health administrative data sets. These studies could focus, 
for instance, on identifying the risk factors for the major 
complications or assess the risk–benefit ratios for new drugs.
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Supplementary material
Algorithm for the identification of prevalent type 2 
diabetes mellitus patients in the SNIIRAM
Algorithm for the identification of the prevalent type 2  dia-
betes mellitus patients in 2012 in the Midi-Pyrénées region:
1. Extraction of the Midi-Pyrénées SNIIRAM data of the 
years 2011, 2012 and 2013.
2. Definition of the patients:
♯1 Long-term disease
  - ongoing in 2012 OR starting in 2012
  -  AND with the E11.X ICD-10 code (Type II 
diabetes mellitus)
♯2 In-hospital diagnosis code in the PMSI database as 
principal diagnosis OR related diagnosis OR associ-
ated diagnosis
  - with an hospital stay entry date in 2011 OR in 2012
  -  AND with the E11.X ICD-10 code (Type II 
diabetes mellitus)
♯3 At least 3 out-of-hospital dispensing of oral anti-
diabetic drugs (ATC code beginning by A10B) with 
traditional packaging during the period 2011-2012
♯4 At least 2 out-of-hospital dispensing of oral antidia-
betic drugs (ATC code beginning by A10B) with large 
packaging during the period 2011-2012
♯5 At least 1 out-of-hospital dispensing of oral antidia-
betic drugs (ATC code beginning by A10B) with large 
packaging during the period 2011-2012 and 1 or 2 out-
hospital dispensing of oral antidiabetic drugs (ATC 
code beginning by A10B) with traditional packaging 
during the period 2011-2012
♯6 Long-term disease
  -  ongoing in 2012 OR starting in 2012 or starting 
during the six months following the first event 
among ♯1, ♯2, ♯3 and ♯4
  -  AND with an ICD-10 code for a disease respon-
sible for secondary diabetes mellitus, that is:
   § E05.X (thyrotoxicosis [hyperthyroidism])
   § OR E24.X (Cushing syndrome)
   §  OR E22.0 (acromegaly and pituitary gigan-
tism) OR E22.9 (hyperfunction of pituitary 
gland, unspecified)
   §  OR E83.1 (disorders of iron metabolism: 
hemochromatosis, excluding anemia by 
iron deficiency (D50) and sideroblastic 
(D64.0-D64.3)
   §  OR M14.5 (arthropathies in other endocrine, 
nutritional and metabolic disorders: in acro-
megaly and pituitary gigantism, hemochro-
matosis, hypothyroidism or thyrotoxicosis 
[hyperthyroidism])
   §  OR K86.0 (alcohol-induced chronic pan-
creatitis), OR K86.1 (other chronic pancre-
atitis), OR K86.8 (other specified diseases 
of pancreas), OR K86.9 (disease of pan-
creas, unspecified), OR K90.3 (pancreatic 
steatorrhea)
   §  OR O24.1 (pre-existing diabetes mellitus, 
non-insulin-dependent), OR O24.9 (diabetes 
mellitus arising in pregnancy)
♯7 In-hospital diagnosis code in the PMSI database as 
principal diagnosis OR related diagnosis OR associ-
ated diagnosis
  -  with an hospital stay entry date during the year 
before the first event among ♯1, ♯2, ♯3 and ♯4 OR 
during the six months following the first event 
among ♯1, ♯2, ♯3 and ♯4
  -  AND with an ICD-10 code for a disease respon-
sible for secondary diabetes mellitus, that is:
   § E05.X (thyrotoxicosis [hyperthyroidism])
   § OR E24.X (Cushing syndrome)
   §  OR E22.0 (acromegaly and pituitary gigan-
tism) OR E22.9 (hyperfunction of pituitary 
gland, unspecified)
   §  OR E83.1 (disorders of iron metabolism: 
hemochromatosis, excluding anemia by 
iron deficiency (D50) and sideroblastic 
(D64.0-D64.3)
   §  OR M14.5 (arthropathies in other endocrine, 
nutritional and metabolic disorders: in acro-
megaly and pituitary gigantism, hemochro-
matosis, hypothyroidism or thyrotoxicosis 
[hyperthyroidism])
   §  OR K86.0 (alcohol-induced chronic pan-
creatitis), OR K86.1 (other chronic pancre-
atitis), OR K86.8 (other specified diseases 
of pancreas), OR K86.9 (disease of pan-
creas, unspecified), OR K90.3 (pancreatic 
steatorrhea)
   §  OR O24.1 (pre-existing diabetes mellitus, 
non-insulin-dependent), OR O24.9 (diabetes 
mellitus arising in pregnancy)
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♯8 At least 3 out-of-hospital dispensing of systemic glu-
cocorticoids (ATC code beginning H02AB) during the 
year before the first event among ♯1, ♯2, ♯3 and ♯4
♯9 At least 3 out-of-hospital dispensing of antiproteases 
(ATC code beginning J05AE) during the year before 
the first event among ♯1, ♯2, ♯3 and ♯4
Definition
(♯1 OR ♯2 OR ♯3 OR ♯4 OR ♯5) AND NOT (♯6 OR ♯7 OR 
♯8 OR ♯9)
Remarks regarding this algorithm
• 3, ♯4 and ♯5 exclude insulin dispensing; indeed these 
drugs are not specific of type 2 diabetes mellitus, and 
therefore cannot be included in this algorithm. Con-
sequently, this will fail in identifying the patients with 
insulin dispensing and without oral antidiabetic drug 
dispensing nor long-term disease or hospitalization with 
type 2 diabetes mellitus diagnosis codes. However, this 
situation seems improbable.
•  Because of data extractions (years 2011-2013), if the first 
event among ♯1, ♯2, ♯3 and ♯4 occurred in 2011, ♯6, ♯7 
and ♯8 cannot be searched during the full year before.
Comparison of this algorithm compared to other 
French algorithms
•  The definition (not validated) used by the CNAMTS to 
identify prevalent diabetic patients (whatever the type of 
diabetes mellitus) is (♯1 or ♯3 or ♯4), extended to all dia-
betes mellitus diagnosis codes and insulins (unpublished 
data).
•  The definition used by the CNAMTS to identify diabe-
tes mellitus (whatever the type of diabetes mellitus) as 
comorbidity in the SNIIRAM for Charlson’s score cal-
culation is (♯1 or ♯2 or ♯3 or ♯4), extended to all diabetes 
mellitus diagnosis codes and insulins, recorded during 
the year before index date.1
•  The definition used in most studies identifying diabetes 
mellitus patients in the SNIIRAM is (♯3 or ♯4).2 Indeed, 
the population of interest is frequently restricted to 
treated patients in epidemiologic studies conducted in 
the SNIIRAM.3
Our algorithm combines all the sources of information 
regarding diabetes mellitus in the SNIIRAM and might be 
more accurate to estimate its prevalence.
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